Project Grant HT94252310059
Award Date
2/1/23
Completion Date
1/31/26
Dollars Obligated
$781K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee,...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
Health Research, Inc. Inc Roswell Park Division Health Research Division (the Division) was awarded a $693,987 project grant from the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420). The grant will fund cancer immunotherapy research from June 1, 2023 through May 31, 2026. Specifically, the Division will investigate strategies to counter solid tumor antigen immune escape using CAR T cell therapies. As a past recipient of Defense Health Agency...
The Defense Health Agency awarded a $168,200 Project Grant to Health Research, Inc. Roswell Park Division under the Military Medical Research and Development program (CFDA 12.420) to investigate alternative polyadenylation as a mediator of therapeutic resistance in lung cancer. The two-year award beginning July 1, 2021 will support research into innovative medical solutions for lung cancer treatment through the study of alternative polyadenylation, a novel area of investigation that could help...
Health Research, Inc. Roswell Park Division received a $780,750 project grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on mechanisms of immune suppression and potential therapies. The three-year award, made on April 1, 2023, will support investigation into how the protein neuritin mediates reprogramming of myeloid cell populations and its role in immune suppression. Through this research, the awardee aims...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,301,250.00 to Health Research, Inc. at its Roswell Park Division in Buffalo, New York. The award supports research to investigate inhibiting the biogenesis of myeloid-derived suppressor cells (MDSC) in order to enhance the efficacy of immunotherapy for triple-negative breast cancer. The performance period for this research...
The Defense Health Agency awarded a $1,561,500 Project Grant to Health Research, Inc. Roswell Park Division for the period of March 15, 2023 through March 14, 2026. The grant will support research into slow-cycling prostate cancer cells in therapy resistance, disease relapse, and metastasis. This award is being made under the Military Medical Research and Development program (CFDA 12.420). This program aims to transform military and public health through innovative medical research solutions for...
Health Research, Inc. Roswell Park Division received a $559,647 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research using microfluidic lung cancer models. The two-year award, made on June 1, 2023 and set to conclude on May 31, 2025, will support investigating novel drug resistance mechanisms in lung cancer through "Microfluidic Lung Cancer On A Chip" models. As a past recipient of Defense...
The Department of the Army Medical Command awarded a $1,080,268 project grant to Health Research-Roswell Park Cancer Institute Division through the Military Medical Research and Development program (CFDA 12.420). The grant funding will support research efforts to target stress pathways in esophagus cancer in order to boost anti-tumor immunity, promote response to therapy, and prolong patient survival. By investigating medical solutions at the molecular level, this research aims to transform...
The Department of the Army Medical Command awarded a $1,419,356 project grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through September 2025 to develop novel immunotherapy approaches to suppress cancer metastasis and recurrence in bone. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...